Revenio Group Oyj - Company Announcement

Revenio Group Corporation: Revenio Group Corporation's Market Cap Segment Change to Mid Cap as of Jan 4, 2016

Revenio Group Corporation, Stock Exchange Release, December 17, 2015 at 15:30

REVENIO GROUP CORPORATION'S MARKET CAP SEGMENT WILL CHANGE TO MID CAP AS OF JAN
4, 2016

Nasdaq has reported today that the yearly evaluation of market cap segments has
been completed. Evaluation has been made based on the companies' average market
cap in November 2015.  According to the evaluation, Revenio Group Corporation's
market cap segment will change from Small Cap to Mid Cap segment. According to
Nasdaq's release market cap segment classification as well as index and
industrial classification is an important method to increase the visibility of
Nasdaq's northern exchange listed companies in Helsinki, Iceland, Copenhagen and
Stockholm.

The changes will take effect on January 4, 2016.

Nasdaq reports that 36 companies will change market cap segment. 25 companies
will move up to a higher market cap segment and 11 companies will move to a
lower market cap segment.
https://newsclient.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=689
469&lang=en

Revenio Group Corporation
Olli-Pekka Salovaara
President&CEO

For further information, please contact:
President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
www.revenio.fi

DISTRIBUTION:
NASDAQ Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish health tech group whose core business is in tonometers. The
Revenio Health Tech segment comprises the business operations of Icare Finland
Oy, Revenio Research Oy and Oscare Medical Oy, which specializes in osteoporosis
screening and monitoring. In addition, Revenio has identified new growth
opportunities relating to health tech in which common denominators are
screening, follow-up and the global need to make cost savings in health care via
preventive measures. Revenio seeks vigorous growth in health technology, both
organically and through acquisitions and mergers.

In 2014, the Revenio Group's net sales totaled MEUR 16.0, with its operating
profit (EBIT) from continuing operations standing at 27.5%. The Revenio Group
Corporation is listed on NASDAQ OMX Helsinki.

[HUG#1974455]